Published • loading... • Updated
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
- Antengene Corporation Limited will present preclinical results from its costimulatory T cell engager platform at the 2026 Society for Immunotherapy of Cancer Annual Meeting.
- The presentation will describe a CD2-based platform that combines a CD3γε/δε-targeting antibody with CD3 masking based on steric hindrance.
- Dr. Bing Hou will give the rapid oral presentation on November 6, 2026.
- The meeting will take place November 4–8, 2026, in Phoenix, Arizona.
Insights by Ground AI
29 Articles
29 Articles
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies,…
·Pennsylvania, United States
Read Full ArticleCoverage Details
Total News Sources29
Leaning Left4Leaning Right2Center16Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
L 18%
C 73%
Factuality
To view factuality data please Upgrade to Premium
